title: Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial.
abstract: BACKGROUND
  New antibacterial agents with activity against pathogenic strains resistant to established antibiotics are needed to treat patients with secondarily infected dermatitis (SID).
  
  
  OBJECTIVE
  We sought to determine the clinical safety and efficacy of topical retapamulin ointment 1% versus oral cephalexin for the treatment of SID.
  
  
  METHODS
  Patients with SID were randomly assigned to retapamulin ointment 1% (twice daily [bid]) for 5 days, or oral cephalexin (500 mg bid) for 10 days. The primary efficacy end point was clinical response at follow-up. Secondary outcomes included microbiologic response at follow-up, safety, and compliance.
  
  
  RESULTS
  Retapamulin was as effective as cephalexin (clinical success rates at follow-up: 85.9% and 89.7%, respectively). Microbiologic success rates at follow-up were 87.2% for retapamulin and 91.8% for cephalexin. Retapamulin was well tolerated and the topical formulation was preferred over the oral drug.
  
  
  CONCLUSIONS
  An imbalance existed in the number of patients with the clinical outcome "unable to determine" (15 retapamulin, 2 cephalexin), mainly because of their failure to attend the study visit. If those who failed to attend visits (who did not withdraw as a result of drug-related events) are removed from the analysis, the clinical success rates are 89.9% for retapamulin and 89.7% for cephalexin.
  
  
  CONCLUSIONS
  Retapamulin ointment 1% (bid) for 5 days was as effective as oral cephalexin (bid) for 10 days in treatment of patients with SID, and was well tolerated.
authors.affiliation: Department of Dermatology and Cutaneous Biology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
authors.forename: Lawrence Charles
authors.initials: LC
authors.lastname: Parish
authors.forename: Joseph Lucius
authors.initials: JL
authors.lastname: Jorizzo
authors.forename: John Jeffrey
authors.initials: JJ
authors.lastname: Breton
authors.forename: Joseph William
authors.initials: JW
authors.lastname: Hirman
authors.forename: Nicole Elizabeth
authors.initials: NE
authors.lastname: Scangarella
authors.forename: Ribhi Mohammad
authors.initials: RM
authors.lastname: Shawar
authors.forename: Scott Matthew
authors.initials: SM
authors.lastname: White
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D002506:Cephalexin / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003872:Dermatitis / Q000150:complications*; D003876:Dermatitis, Atopic / Q000150:complications; D004224:Diterpenes; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D016106:Methicillin Resistance; D008875:Middle Aged; D009824:Ointments; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000209:etiology; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000209:etiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D013290:Streptococcal Infections / Q000188:drug therapy* / Q000209:etiology; D013297:Streptococcus pyogenes / Q000187:drug effects / Q000302:isolation & purification*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004224:Diterpenes; D009824:Ointments; C508887:retapamulin; D002506:Cephalexin